Applications Published 9 August 2000

Published: 25-Feb-2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).

  • Neomycin/disaccharide water solution for enteroclysis in hepatic encephalopathy
    Labruzzo, Carla; Vicidomini, Francesco 1024798*

  • Method for treating disease-related or drug-induced dyskinesias
    Warner-Lambert 1024799*

  • Thyroxine analogues having no significant hormonal activity to treat malignant tumours
    Octamer 1024800*

  • Method fo regualting size and growth of vascularised normal tissue
    Children's Medical Centre; Massachusetts Institute of Technology 1024801*

  • Flavonoids for cystic fibrosis therapy
    Children's Hospital Medical Centre of Northern California 1024803*

  • MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels
    Bristol-Myers Squibb 1024804*

  • Use of coumarin derivatives for the treatment of digestive tract disorders
    Bio-Monde Preparations 1024805*

  • Use of non-immunosuppresive compounds for promoting nerve regeneration
    Oregon Health Sciences 1024806*

  • Pharmaceutical preparations containing hdrosoluble ketoprofen salts and their application
    Errekapppa Euroterapici 1024808*

  • Use of immunomodulating agents
    Lauras 1024809*

  • Method for optimising retinal and optic nerve health
    Merck 1024810*

  • Novel benzodiazepine derivatives as antiarrhythmic agents
    Merck 1024811*

  • Compsns containing lysophosphatidic acids which inhibit apoptosis and uses thereof
    LXR Biotechnology 1024812*

  • Use of sulphated oligosaccharides as inhibitors of cardiovascular diseases
    The Australian National University 1024813*

  • Use of antifungal agents for the toical treatment of fungus-induced mucositis
    Ponikau, Jens 1024814*

  • Pharmaceutical compsns for oral administration of iodine
    Symbollon Corp 1024815*

  • Kits and methods for alleviation of lower gastrointestinal disorders in human patients
    Rubin, Walter; Dave, Bhavin 1024816*

  • Method of curing AIDS with tetrasilver tetroxide molecular crystal devices
    Antelman Technologies 1024818*

  • Citrus peel extracts as inhibitor of acyl CoA-cholesterol-O-acyl-transferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall, and preventative of treating agent for hepatic diseases
    Korea Institute of Science and Technology 1024819*

  • Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterised by a pathologically underweight condition
    Janus Pharmaceuticals 1024820*

  • Novel prokaryotic polynucleotides, polypeptides and and their uses
    SmithKline Beecham 1024821*

  • Prevention and treatment of adhesion formulation
    Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek 1024823*

  • Solid disposal vaccine compsn for oral delivery
    RP Scherer 1024824*

  • Passive immunisation against (Clostridium difficile) disease
    Oravax 1024826*

  • Compsns and methods for systemic delivery of oral vaccines and therapeutic agents
    Thomas Jefferson University 1024827*

  • Novel PHES(Beta)
    SmithKline Beecham 1024828*

  • Tolerogenic fragments of natural allergens
    CBF Leti 1024829*

  • Antigen vectors in the form of multilamellar vesicles
    Capsulis 1024830*

  • Application of TNF antagonists as medicaments for treating septic diseases
    Knoll 1024831*

  • Pharmaceutical compsn containing acid addition salt of basic drugs
    Farmarc Nederland 1024833*

  • Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
    Immunologic Pharmaceuticals 1024834*

  • J-chain and analogues as epithelial cell targeting conjugates
    EPIcyte Pharmaceuticals 1024835*

  • Method of delivering genes to antigen presenting cells of the skin
    Genetic Immunity 1024836*

  • Ultrasound imaging with contrast agent targeted to microvasculature and a vasoldilator drug
    Nycomed Imaging 1024837*

  • Stable radioiodine conjugates and methods for their synthesis
    Immunomedics 1024838*

  • Reverse phase connective tissue repair compsn
    Gensci OrthoBiologics 1024839*

  • Bone substitute materials
    Philips-Origen Ceramic Technology 1024840*

  • (Alpha)-aryl-(N)-alkylnitrones and pharmaceutical compsns containing the same
    Centaur Pharmaceuticals 1025079*

  • Novel vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilisation thereof for producing medicaments
    Schering 1025082*

  • Process for stereoselective synthesis of prostacyclin derivatives
    United Therapeutics Corp 1025083*

  • Method for purifying 4-amino-piperidines
    BASF 1025084*

  • Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
    Ortho-McNeil Pharmaceutical 1025085*

  • Benzamidine derivatives as factor XA inhibitors
    Merck 1025086*

  • Substituted isoquinoline derivatives and their use as anticonvulsants
    SmithKline Beecham 1025087*

  • Imidazole derivatives and their use as farnesyl protein transferase inhibitors
    AstraZeneca 1025088*

  • Vitronectin receptor antagonists
    SmithKline Beecham 1025090*

  • Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
    Krenitsky Pharmaceutical 1025091*

  • Preparation of asymmetric cyclic ureas through a monoacylated diamine intermediate
    DuPont Pharmaceuticals 1025092*

  • Substituted indan derivatives
    AstraZeneca 1025094*

  • Substituted chroman derivatives
    AstraZeneca 1025095*

  • Benzothiphenes
    Eli Lilly 1025098*

  • Bis-quaternary ammonium derivatives as neuromuscular relaxants
    Gyermek, Laszlo; Lee, Chingmuh; Cho, Young-Moon 1025099*

  • 3-substituted tetrahydropyridopyrimidone derivatives, method for producing same, and their usesBASF 1025100*

  • Naphtho-imidazo 1,2-A]pyrimidin derivatives, their preparation and their use in treating central nervous system disorders
    Ortho-McNeil Pharmaceutical 1025101*

  • Bycyclic kinase inhibitors
    F Hoffman-La Roche 1025102*

  • Novel polymorphic forms of cipamfylline
    SmithKline Beecham 1025103*

  • Condensed benzothiopyranic compounds
    Pharmacia & Upjohn 1025105*

  • Allosteric adenosine receptor modulators
    Medco Research 1025106*

  • Photochromic compounds
    James Robinson 1025107*

  • Photochromic spiro(indoline) fluoroanthenoxazine compounds
    Transitions Optical 1025108*

  • Benzoxazine derivatives, preparation and application in therapy
    Sanofi-Synthelabo 1025109*

  • Improved process for performing polynucletide separations
    Transgenomic 1025113*

  • Novel aspartame crystals and process for the preparation thereof
    Yissum Research Development Company of the Hebrew University of Jerusalem 1025117*

  • Spacer peptides and membranes containing same
    Merck 1025118*

  • Histogranin peptide and their analgesic use
    University of Ottawa 1025119*

  • Methods, kits and compsns pertaining to PNA molecular beacons
    Boston Probes 1025120*

  • Peptides capable of inhibiting the interaction between presenilins and the (beta)-amyloid peptide or its precursors
    Aventis Pharma 1025121*

  • Fibroblast growth factor with hepatocyte proliferation activity
    Itoh, Nobuyuki 1025122*

  • Method for the production of human blood cytokines
    Klehr, Nikolaus 1025123*

  • Low-toxicity human interferon-alpha analogues
    Pepgen Corp; University of Florida 1025124*

  • Aggregates of human insulin derivatives
    Novo Nordisk 1025125*

  • Purification of molecules
    Genentech 1025126*
  • You may also like